Glucagon-Like Peptide 1 Receptor Agonists and the Deepening Health Equity Divide in America.
Publication Title
American journal of health promotion : AJHP
Document Type
Article
Publication Date
6-1-2025
Keywords
oregon; portland; cards; cards publication; diversity
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have changed the landscape of diabetes management, obesity treatment, and cardiometabolic health. As a result, GLP-1 utilization has increased significantly over the past few years. However, emerging evidence raises questions about the potential of these medications to widen existing health disparities. Cost, insurance status, and structural racism all are barriers to access, and these barriers hit hardest on underserved communities who are most in need of these drugs. This article discusses potential evidence of disparities in GLP=1 medication access, utilization, and availability, as well as potential solutions and frameworks that can be adopted with hopes of mitigating these disparities.
Area of Special Interest
Cardiovascular (Heart)
Area of Special Interest
Kidney & Diabetes
Specialty/Research Institute
Center for Cardiovascular Analytics, Research and Data Science (CARDS)
Specialty/Research Institute
Cardiology
Specialty/Research Institute
Pharmacy
DOI
10.1177/08901171251335507b
